1. International Diabetes Federation 2006 Available from www.idf.org
2. 1993 The effect of intensive treatment of diabetes on the development and
progression of long-term complications in insulin-dependent diabetes mellitus.
The Diabetes Control and Complications Trial Research Group.NEngl J Med
329:977–986
3. 1995 The relationship of glycemic exposure (HbA1c) to the risk of development
and progression of retinopathy in the diabetes control and complications
trial. Diabetes 44:968–983
4. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y,
Furuyoshi N, ShichiriM1995 Intensive insulin therapy prevents the progression
of diabetic microvascular complications in Japanese patients with noninsulin-
dependent diabetes mellitus: a randomized prospective 6-year study.
Diabetes Res Clin Pract 28:103–117
5. 1998 Intensive blood-glucose control with sulphonylureas or insulin compared
with conventional treatment and risk of complications in patients with type 2
diabetes (UKPDS 33).UKProspective Diabetes Study (UKPDS) Group. Lancet
[Erratum (1999) 354:602] 352:837–853
6. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, Krahenbhul S,
Diem P 2006 Glycemic control and macrovascular disease in types 1 and 2
diabetes mellitus: meta-analysis of randomized trials. Am Heart J 152:27–38
7. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R,
Zinman B 2006 Management of hyperglycemia in type 2 diabetes: a consensus
algorithm for the initiation and adjustment of therapy: a consensus statement
from the American Diabetes Association and the European Association for the
Study of Diabetes. Diabetes Care 29:1963–1972
8. Sorkin JD, Muller DC, Fleg JL, Andres R 2005 The relation of fasting and 2-h
postchallenge plasma glucose concentrations to mortality: data from the Baltimore
Longitudinal Study of Aging with a critical review of the literature.
Diabetes Care 28:2626–2632
9. Shiraiwa T, Kaneto H, Miyatsuka T, Kato K, Yamamoto K, Kawashima A,
Kanda T, Suzuki M, Imano E, Matsuhisa M, Hori M, Yamasaki Y 2005
Postprandial hyperglycemia is a better predictor of the progression of diabetic
retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care
28:2806–2807
10. Levitan EB, Song Y, Ford ES, Liu S 2004 Is nondiabetic hyperglycemia a risk
factor for cardiovascular disease?Ameta-analysis of prospective studies. Arch
Intern Med 164:2147–2155
11. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, RuppM2004
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients:
meta-analysis of seven long-term studies. Eur Heart J 25:10–16
12. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R,
Nappo F, Lucarelli C, D’Onofrio F 1997 Vascular effects of acute hypergly-
cemia in humans are reversed by L-arginine. Evidence for reduced availability
of nitric oxide during hyperglycemia. Circulation 95:1783–1790
13. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC,
Creager MA 1998 Acute hyperglycemia attenuates endothelium-dependent
vasodilation in humans in vivo. Circulation 97:1695–1701
14. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D 2001 Acute hyperglycemia
induces an oxidative stress in healthy subjects. J Clin Invest 108:
635–636
15. Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A 2005
Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic
patients. Circulation 112:179–184
16. 1996 The absence of a glycemic threshold for the development of long-term
complications: the perspective of the Diabetes Control and Complications
Trial. Diabetes 45:1289–1298
17. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden
D, TurnerRC,HolmanRR2000Association of glycaemia with macrovascular
and microvascular complications of type 2 diabetes (UKPDS 35): prospective
observational study. BMJ 321:405–412
18. Erlinger TP, Brancati FL 2001 Postchallenge hyperglycemia in a national sample
of U.S. adults with type 2 diabetes. Diabetes Care [Erratum (2002) 25:249]
24:1734–1738
19. Bonora E, Corrao G, Bagnardi V, Ceriello A, Comaschi M, Montanari P,
Meigs JB 2006 Prevalence and correlates of post-prandial hyperglycaemia in
a large sample of patients with type 2 diabetes mellitus. Diabetologia 49:846–
854
20. 2007 AACE Diabetes Mellitus Clinical Practice Guidelines Task Force, American
Association of Clinical Endocrinologists Medical Guidelines for Clinical
Practice of the Management of Diabetes Mellitus. Endocr Pract 13(Suppl 1):
5-68
21. 2006 Global guideline for type 2 diabetes. International Diabetes Federation
Task Force on Clinical Guidelines, International Diabetes Federation. http://
www.idf.org
22. O’Leary LH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK
1999 Carotid-artery intima and media thickness as a risk factor for myocardial
infarction and stroke in older adults. Cardiovascular Health Study Collaborative
Research Group. N Engl J Med 340:14–22
23. Esposito K, Giugliano D, Nappo F, Marfella R 2004 Regression of carotid
atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes
mellitus. Circulation 110:214–219
24. Zar JH 1999 Biostatistical analysis. 4th ed. Upper Saddle River, NJ: Prentice
Hall Inc.; 663
25. 1999 A desktop guide to type 2 diabetes mellitus. European Diabetes Policy
Group 1999. Diabet Med 16:716–730
26. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, HanefeldM
2000 Postchallenge plasma glucose and glycemic spikes are more strongly
associated with atherosclerosis than fasting glucose or HbA1c levels. Diabetes
Care 23:1830–1834
27. Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, Rosamond
W, Crow RS, Rautaharju PM, Heiss G 1995 Arterial wall thickness
is associated with prevalent cardiovascular disease in middle-aged adults: the
Atherosclerosis Risk in Communities (ARIC) Study. Stroke 26:386–391
28. Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Selzer RH,
Blankenhom DH, Hodis HN 1996 Progression of coronary artery disease
predicts clinical coronary events: long-term follow-up from the Cholesterol
Lowering Atherosclerosis Study. Circulation 93:34–41
29. Weyer C, Bogardus C, Mott DM, Pratley RE 1999 The natural history of
insulin secretory dysfunction and insulin resistance in the pathogenesis of type
2 diabetes mellitus. J Clin Invest 104:787–794
30. Pratley RE, Weyer C 2001 The role of impaired early insulin secretion in the
pathogenesis of type II diabetes mellitus. Diabetologia 44:929–945
31. Monnier L, Collette C, Dunseath GJ, OwensDR2007 The loss of postprandial
glycemic control precedes stepwise deterioration of fasting with worsening
diabetes. Diabetes Care 30:263–269
32. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Va¨ha¨ talo M, Virtamo
H, Nikkila¨ K, Tulokas T, Hulme S, Hardy K, McNulty S,Ha¨nninen J, Leva¨nen
H, Lahdenpera¨ S, Lehtonen R, Ryysy L 2006 Insulin glargine or NPH combined
with metformin in type 2 diabetes: the LANMET study. Diabetologia
49:442–451
33. Polonsky KS, Given BD, Van Cauter E 1988 Twenty-four-hour profiles and
pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest
81:442–448
34. American Diabetes Association 2001 Postprandial blood glucose. American
Diabetes Association. Diabetes Care 24:775–778
35. American Diabetes Association 2005 Standards of medical care in diabetes.
Diabetes Care [Erratum (2005) 28:990] 28(Suppl 1):S4–S36
36. Gerich JE 2003 Clinical significance, pathogenesis, and management of postprandial
hyperglycemia. Arch Intern Med 163:1306–1316
37. Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G,
Costa G, Trovati M 2006 Postprandial blood glucose is a stronger predictor
of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus,
particularly in women: lessons from the San Luigi Gonzaga Diabetes Study.
J Clin Endocrinol Metab 91:813–819
38. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T,
Kugiyama K, Ogawa H, Yasue H 1999 Hyperglycemia rapidly suppresses
flow-mediated endothelium-dependent vasodilation of brachial artery. J Am
Coll Cardiol 34:146–154
39. Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Esposito K,
Giugliano D 2004 Effect of postprandial hypertriglyceridemia and hyperglycemia
on circulating adhesion molecules and oxidative stress generation and
the possible role of simvastatin treatment. Diabetes 53:701–710
40. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C 2006
Activation of oxidative stress by acute glucose fluctuations compared with
sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:
1681–1687
41. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOPNIDDM
Trial Research Group 2002 Acarbose for prevention of type 2 diabetes
mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077
42. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOPNIDDM
Trial Research Group 2004 Acarbose for the prevention of type 2
diabetes, hypertension and cardiovascular disease in subjects with impaired
glucose tolerance: facts and interpretations concerning the critical analysis of
the STOP-NIDDM Trial data. Diabetologia 47:969–975
43. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-
Kurktschiev T 2004 Acarbose slows progression of intima-media thickness of
the carotid arteries in subjects with impaired glucose tolerance. Stroke 355:
1073–1078